Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 563-573

  Verma, Bhavna ^a   Hawkins, Oriana E ^b   Neethling, Francisca A ^c   Caseltine, Shannon L ^c   Largo, Sherly R ^c   Hildebrand, William H ^b   Weidanz, Jon A ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Receptor Logic Inc   (United States)

Author keywords

Human leukocyte antigens; Major histocompatibility complex; Mass spectrometry; Monoclonal antibody; Orthotopic model; P68 RNA helicase dead box protein; Peptide; T cell epitope discovery; T cell receptor mimics; Therapeutic effect

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; RL6A T LYMPHOCYTE RECEPTOR MIMIC ANTIBODY; T LYMPHOCYTE RECEPTOR; TYROSYLLEUCYLLEUCYLPROLYLALANYLISOLEUCYLVALYLHISTIDINYLISOLEUCINE; UNCLASSIFIED DRUG; CANCER VACCINE; DEAD BOX PROTEIN; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG RESEARCH; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLUENZA; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; VALIDATION PROCESS; ANIMAL; BREAST; BREAST TUMOR; CYTOTOXIC T LYMPHOCYTE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; NUDE MOUSE; PATHOLOGY; SURFACE PLASMON RESONANCE; VALIDATION STUDY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CANCER VACCINES; DEAD-BOX RNA HELICASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77449083338     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0774-8     Document Type: Article

References (46)

1. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA (2008) Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 14:502-508 (Pubitemid 351226119)
2. Halama N, Herrmann C, Jaeger D, Herrmann T (2008) Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res 28:4111-4115
3. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334
4. Kabbinavar F, Irl C, Zurlo A, Hurwitz H (2008) Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 75:215-223
5. Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL Jr, Boehm KA et al. (2008) Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clin Colorectal Cancer 7:390-397
6. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113-1120
7. BaselgaJ,NortonL,AlbanellJ,KimYM,MendelsohnJ(1998) Recombinanthumanizedanti-HER2antibody(Herceptin) enhancestheantitumoractivityofpaclitaxelanddoxorubicinagainstHER2/ neuoverexpressinghumanbreastcancerxenografts.CancerRes58:2825- 2831(Pubitemid28311914)
8. Shastri N, Schwab S, Serwold T (2002) Producing nature's genechips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol 20:463-493 (Pubitemid 34293432)
9. Brodsky FM, Lem L, Bresnahan PA (1996) Antigen processing and presentation. Tissue Antigens 47:464-471
10. Alexander RB, Brady F, Leffell MS, Tsai V, Celis E (1998) Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51:150-157 (Pubitemid 28092528)
11. WolfelT,HauerM,KlehmannE,BrichardV,AckermannB,KnuthA,BoonT, MeyerZumBuschenfeldeKH(1993) AnalysisofantigensrecognizedonhumanmelanomacellsbyA2- restrictedcytolyticTlymphocytes(CTL).IntJCancer55:237-244(Pubitemid23296022)
12. Wahl A, Weidanz J, Hildebrand W (2006) Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev Proteomics 3:641-652 (Pubitemid 46021200)
13. Kessler JH, Melief CJ (2007) Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21:1859-1874 (Pubitemid 47299958)
14. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ, Stoehr P, Marsh SG (2003) IMGT/HLA and IMGT/ MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 31:311-314 (Pubitemid 36150392)
15. Robinson J, Marsh SG (2003) HLA informatics: accessing HLA sequences from sequence databases. Methods Mol Biol 210:3-21
16. Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T (2002) Identification of HLA-A3restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer 102:499-506 (Pubitemid 35316005)
17. Rosenberg SA (1996) Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88:1635-1644
18. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261-1263
19. Hawkins OE, Vangundy RS, Eckerd AM, Bardet W, Buchli R, Weidanz JA, Hildebrand WH (2008) Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res 7:1445-1457
20. HickmanHD,LuisAD,BuchliR,FewSR,SathiamurthyM,VanGundyRS,GibersonCF, HildebrandWH(2004)Towardadefinitionofself: proteomicevaluationoftheclassIpeptiderepertoire.JImmunol172:2944- 2952(Pubitemid38263681)
21. PrillimanKR,JacksonKW,LindseyM,WangJ,CrawfordD,HildebrandWH(1999) HLA-B15peptideligandsarepreferentiallyanchoredattheirCtermini.JImmunol162: 7277-7284(Pubitemid29277701)
22. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S (1996) A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci USA 93:1820-1824 (Pubitemid 26079838)
23. Zhong G, Reis e Sousa C, Germain RN (1997) Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro. J Exp Med 186:673-682
24. WeidanzJA,NguyenT,WoodburnT,NeethlingFA,ChirivaInternatiM,HildebrandWH, LustgartenJ(2006)Levelsofspecificpeptide- HLAclassIcomplexpredictstumorcellsusceptibility-CTLkilling.JImmunol177: 5088-5097(Pubitemid44527579)
25. Weidanz JA, Piazza P, Hickman-Miller H, Woodburn D, Nguyen T, Wahl A, Neethling F, Chiriva-Internati M, Rinaldo CR, Hildebrand WH (2007) Development and implementation of a direct detection, quantitation and validation system for class I MHC selfpeptide epitopes. J Immunol Methods 318:47-58 (Pubitemid 46026805)
26. Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W (1997) Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 45:379-385 (Pubitemid 27163177)
27. Wei ML, Cresswell P (1992) HLA-A2 molecules in an antigenprocessing mutant cell contain signal sequence-derived peptides. Nature 356:443-446
28. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzerWilliams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96
29. WittmanVP,WoodburnD,NguyenT,NeethlingFA,WrightS,WeidanzJA(2006) Antibodytargeting-aclassIMHC-peptideepitopepromotestumorcelldeath.JImmunol177: 4187-4195(Pubitemid44359954)
30. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207 (Pubitemid 40174238)
31. Clark CE, Vonderheide RH (2005) Getting to the surface: a link between tumor antigen discovery and natural presentation of peptide-MHC complexes. Clin Cancer Res 11:5333-5336
32. Mosca PJ, Hobeika AC, Clay TM, Morse MA, Lyerly HK (2001) Direct detection of cellular immune responses to cancer vaccines. Surgery 129:248-254 (Pubitemid 32200054)
33. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH (2009) HLA class I molecules consistently present internal influenza epitopes. Proc Natl Acad Sci USA 106:540-545
34. Parsons R, Lelic A, Hayes L, Carter A, Marshall L, Evelegh C, Drebot M, Andonova M, McMurtrey C, Hildebrand W et al. (2008) The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes. J Immunol 181:1563-1572
35. Heinlein UA (1998) Dead box for the living. J Pathol 184:345-347
36. EndohH,MaruyamaK,MasuhiroY,KobayashiY,GotoM,TaiH,YanagisawaJ,MetzgerD, HashimotoS,KatoS(1999) Purificationandidentificationofp68RNAhelicaseactingasatranscriptionalcoactiv atorspecificfortheactivationfunction1ofhumanestrogenreceptoralpha.MolCellBiol19: 5363-5372(Pubitemid29339895)
37. RosslerOG,HlochP,SchutzN,WeitzeneggerT,StahlH(2000) Structureandexpressionofthehumanp68RNAhelicasegene.NucleicAcidsRes28: 932-939(Pubitemid30085319)
38. Nicol SM, Causevic M, Prescott AR, Fuller-Pace FV (2000) The nuclear DEAD box RNA helicase p68 interacts with the nucleolar protein fibrillarin and colocalizes specifically in nascent nucleoli during telophase. Exp Cell Res 257:272-280 (Pubitemid 30390478)
39. Kitamura A, Nishizuka M, Tominaga K, Tsuchiya T, Nishihara T, Imagawa M (2001) Expression of p68 RNA helicase is closely related to the early stage of adipocyte differentiation of mouse 3T3-L1 cells. Biochem Biophys Res Commun 287:435-439 (Pubitemid 32917617)
40. Liu ZR (2002) p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5' splice site duplex. Mol Cell Biol 22:5443-5450
41. Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, Wardrop J, Gregory DJ, Lane DP, Perkins ND, Fuller-Pace FV (2005) The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J 24:543-553 (Pubitemid 40343256)
42. Camats M, Guil S, Kokolo M, Bach-Elias M (2008) P68 RNA helicase (DDX5) alters activity of cis- and trans-acting factors of the alternative splicing of H-Ras. PLoS ONE 3:e2926
43. Yang L, Lin C, Liu ZR (2005) Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Mol Cancer Res 3:355-363 (Pubitemid 40905627)
44. Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, Steele RJ, Fuller-Pace FV (2001) Overexpression and polyubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene 20:7734-7743 (Pubitemid 33121946)
45. Denkberg G, Reiter Y (2006) Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation. Autoimmun Rev 5:252-257 (Pubitemid 43668459)
46. CohenCJ,SarigO,YamanoY,TomaruU,JacobsonS,ReiterY(2003) DirectphenotypicanalysisofhumanMHCclassIantigenpresentation:visualization, quantitation,andinsitudetectionofhumanviralepitopesusingpeptide-specific, MHC-restrictedhumanrecombinantantibodies.JImmunol170:4349- 4361(Pubitemid36428205)